Immobilisation of an anti-platelet adhesion ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
Immobilisation of an anti-platelet adhesion and anti-thrombotic drug (EP224283) on polydopamine coated vascular stent promoting anti-thrombogenic properties
Auteur(s) :
Bricout, Nicolas [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Chai, Feng [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Sobocinski, Jonathan [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Hertault, Adrien [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Laure, William [Auteur]
Unité Matériaux et Transformations - UMR 8207 [UMET]
Ung, Alexandre [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Woisel, Patrice [Auteur]
Unité Matériaux et Transformations - UMR 8207 [UMET]
Lyskawa, Joel [Auteur]
Unité Matériaux et Transformations - UMR 8207 [UMET]
Blanchemain, Nicolas [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Chai, Feng [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Sobocinski, Jonathan [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Hertault, Adrien [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Laure, William [Auteur]
Unité Matériaux et Transformations - UMR 8207 [UMET]
Ung, Alexandre [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Woisel, Patrice [Auteur]
Unité Matériaux et Transformations - UMR 8207 [UMET]
Lyskawa, Joel [Auteur]
Unité Matériaux et Transformations - UMR 8207 [UMET]
Blanchemain, Nicolas [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Titre de la revue :
Materials Science and Engineering: C
Pagination :
110967
Éditeur :
Elsevier
Date de publication :
2020-08-01
ISSN :
0928-4931
Mot(s)-clé(s) en anglais :
Stent
Thrombosis
Platelet adhesion
Polydopamine
EP224283
Surface functionalisation
Thrombosis
Platelet adhesion
Polydopamine
EP224283
Surface functionalisation
Discipline(s) HAL :
Chimie/Matériaux
Sciences de l'ingénieur [physics]/Matériaux
Chimie/Polymères
Sciences de l'ingénieur [physics]/Génie des procédés
Sciences de l'ingénieur [physics]/Matériaux
Chimie/Polymères
Sciences de l'ingénieur [physics]/Génie des procédés
Résumé en anglais : [en]
Current vascular drug-eluting stents based on immuno-proliferative drugs would reduce the rate of in-stent restenosis (ISR) but may be associated with a higher risk of acute stent thrombosis due to non-selective activity. ...
Lire la suite >Current vascular drug-eluting stents based on immuno-proliferative drugs would reduce the rate of in-stent restenosis (ISR) but may be associated with a higher risk of acute stent thrombosis due to non-selective activity. In this paper, we aimed to develop a polydopamine (PDA) coated chromium‑cobalt (CoCr) stent functionalised with EP224283 (Endotis Pharma SA), which combines both a GPIIbIIIa antagonist (tirofiban moiety) and a factor Xa inhibitor (idraparinux moiety) to reduce acute stent thrombosis.PDA-coated chromium‑cobalt (CoCr) samples were first immersed in a polyethylenimine (PEI, pH 8.5) solution to increase amine function density (36.0 ± 0.1 nmol/cm2) on the CoCr surface. In a second step, avidin was grafted onto CoCr-PDA-PEI through the biotin linkage (strategy 1) or directly by coupling reactions (strategy 2). The HABA titration proved the fixation of biotin onto CoCr-PDA-PEI surface with a density of 0.74 nmol/cm2. The fixation of avidin was demonstrated by water contact angle (WCA) and surface plasmon resonance (SPR). SEM micrograph shows the flexibility of the thin layer coated onto the stent after balloon inflation. Independently of the strategy, a qualitative SEM analysis showed a reduction in platelet activation when the molecule EP224283 was immobilised on avidin. In parallel, the measurement of anticoagulant activity (anti-Xa) revealed a higher anti-factor Xa activity (2.24 IU/mL vs. 0.09 IU/mL in control) when EP224283 was immobilised on avidin. Interestingly, after seven days of degradation, the anticoagulant activity was persistent in both strategies and looked more important with the strategy 2 than in strategy 1.Throughout this work, we developed an innovative vascular stent through the immobilisation of EP224283 onto CoCr-PDA-PEI-(avidin) system, which provides a promising solution to reduce ISR and thrombosis after stent implantation.Lire moins >
Lire la suite >Current vascular drug-eluting stents based on immuno-proliferative drugs would reduce the rate of in-stent restenosis (ISR) but may be associated with a higher risk of acute stent thrombosis due to non-selective activity. In this paper, we aimed to develop a polydopamine (PDA) coated chromium‑cobalt (CoCr) stent functionalised with EP224283 (Endotis Pharma SA), which combines both a GPIIbIIIa antagonist (tirofiban moiety) and a factor Xa inhibitor (idraparinux moiety) to reduce acute stent thrombosis.PDA-coated chromium‑cobalt (CoCr) samples were first immersed in a polyethylenimine (PEI, pH 8.5) solution to increase amine function density (36.0 ± 0.1 nmol/cm2) on the CoCr surface. In a second step, avidin was grafted onto CoCr-PDA-PEI through the biotin linkage (strategy 1) or directly by coupling reactions (strategy 2). The HABA titration proved the fixation of biotin onto CoCr-PDA-PEI surface with a density of 0.74 nmol/cm2. The fixation of avidin was demonstrated by water contact angle (WCA) and surface plasmon resonance (SPR). SEM micrograph shows the flexibility of the thin layer coated onto the stent after balloon inflation. Independently of the strategy, a qualitative SEM analysis showed a reduction in platelet activation when the molecule EP224283 was immobilised on avidin. In parallel, the measurement of anticoagulant activity (anti-Xa) revealed a higher anti-factor Xa activity (2.24 IU/mL vs. 0.09 IU/mL in control) when EP224283 was immobilised on avidin. Interestingly, after seven days of degradation, the anticoagulant activity was persistent in both strategies and looked more important with the strategy 2 than in strategy 1.Throughout this work, we developed an innovative vascular stent through the immobilisation of EP224283 onto CoCr-PDA-PEI-(avidin) system, which provides a promising solution to reduce ISR and thrombosis after stent implantation.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :
Fichiers
- https://hal.univ-lille.fr/hal-02877605/document
- Accès libre
- Accéder au document
- https://doi.org/10.1016/j.msec.2020.110967
- Accès libre
- Accéder au document
- https://doi.org/10.1016/j.msec.2020.110967
- Accès libre
- Accéder au document
- https://hal.univ-lille.fr/hal-02877605/document
- Accès libre
- Accéder au document
- https://doi.org/10.1016/j.msec.2020.110967
- Accès libre
- Accéder au document
- https://doi.org/10.1016/j.msec.2020.110967
- Accès libre
- Accéder au document
- https://doi.org/10.1016/j.msec.2020.110967
- Accès libre
- Accéder au document
- https://doi.org/10.1016/j.msec.2020.110967
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- S092849311931776X.pdf
- Accès libre
- Accéder au document
- j.msec.2020.110967
- Accès libre
- Accéder au document